137 related articles for article (PubMed ID: 11555696)
1. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris.
Sheffield WP; Smith IJ; Syed S; Bhakta V
Blood Coagul Fibrinolysis; 2001 Sep; 12(6):433-43. PubMed ID: 11555696
[TBL] [Abstract][Full Text] [Related]
2. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540
[TBL] [Abstract][Full Text] [Related]
3. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.
Mo W; Zhang YL; Chen HS; Wang LS; Song HY
J Thromb Thrombolysis; 2009 Aug; 28(2):230-7. PubMed ID: 18998199
[TBL] [Abstract][Full Text] [Related]
4. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY
Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158
[TBL] [Abstract][Full Text] [Related]
5. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin.
Syed S; Schuyler PD; Kulczycky M; Sheffield WP
Blood; 1997 May; 89(9):3243-52. PubMed ID: 9129029
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of RGD-hirudin binding to thrombin: Tyr3 and five C-terminal residues are crucial for inhibiting thrombin activity.
Huang Y; Zhang Y; Zhao B; Xu Q; Zhou X; Song H; Yu M; Mo W
BMC Struct Biol; 2014 Dec; 14():26. PubMed ID: 25526801
[TBL] [Abstract][Full Text] [Related]
7. Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta.
Sheffield WP; Gataiance S; Eltringham-Smith LJ
Thromb Res; 2007; 119(2):195-207. PubMed ID: 16478628
[TBL] [Abstract][Full Text] [Related]
8. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner.
Peter K; Gupta A; Nordt T; Bauer S; Runge MS; Bode C
J Cardiovasc Pharmacol; 2003 Aug; 42(2):237-44. PubMed ID: 12883328
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin by hirudin genetically fused to wild-type or mutant antithrombin.
Syed S; Kelly KE; Sheffield WP
Thromb Res; 1996 Dec; 84(6):419-29. PubMed ID: 8987163
[TBL] [Abstract][Full Text] [Related]
10. [Construction and expression of a fusion protein made of tissue-type plasminogen activator and hirudin in Pichia pastoris].
Yu AP; Shi BX; Dong CN; Jiang ZH; Wu ZZ
Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):553-7. PubMed ID: 16176091
[TBL] [Abstract][Full Text] [Related]
11. Expression, purification, and mass spectrometric analysis of 15N, 13C-labeled RGD-hirudin, expressed in Pichia pastoris, for NMR studies.
Huang Y; Zhang Y; Wu Y; Wang J; Liu X; Dai L; Wang L; Yu M; Mo W
PLoS One; 2012; 7(8):e42207. PubMed ID: 22879918
[TBL] [Abstract][Full Text] [Related]
12. Isolation of thrombin inhibitor from the leech Hirudinaria manillensis.
Electricwala A; Sawyer RT; Jones CP; Atkinson T
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):83-9. PubMed ID: 1773002
[TBL] [Abstract][Full Text] [Related]
13. Overproduction of 15N-labeled r-RGD-hirudin in pichia pastoris for NMR studies.
Wang J; Zhang Y; Li S; Liu X; Yan X; Song H; Yu M; Dai L; Mo W
Protein Pept Lett; 2010 Oct; 17(10):1228-33. PubMed ID: 20450489
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant activity of synthetic hirudin peptides.
Maraganore JM; Chao B; Joseph ML; Jablonski J; Ramachandran KL
J Biol Chem; 1989 May; 264(15):8692-8. PubMed ID: 2722794
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
16. Purification and identification of recombinant hirudin and its degradation products expressed in Pichia pastoris.
Zhou WB; Zhang YX
Prep Biochem Biotechnol; 2004 Aug; 34(3):239-52. PubMed ID: 15461140
[TBL] [Abstract][Full Text] [Related]
17. Production and characterization of hirudin variant-1 by SUMO fusion technology in E. coli.
Lu W; Cai X; Gu Z; Huang Y; Xia B; Cao P
Mol Biotechnol; 2013 Jan; 53(1):41-8. PubMed ID: 22371262
[TBL] [Abstract][Full Text] [Related]
18. Efficient targeted anticoagulant with active RGD motif.
Bi Q; Zhou X; Cen X; Qu H; Luo J; Huang Y; Zhu S
Thromb Res; 2007; 120(4):541-7. PubMed ID: 17222892
[TBL] [Abstract][Full Text] [Related]
19. A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.
Marques JA; George JK; Smith IJ; Bhakta V; Sheffield WP
Thromb Haemost; 2001 Sep; 86(3):902-8. PubMed ID: 11583325
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and secretion of hirudin by Streptomyces lividans.
Bender E; Vogel R; Koller KP; Engels J
Appl Microbiol Biotechnol; 1990 Nov; 34(2):203-7. PubMed ID: 1367034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
